<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23877837</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">1422-0067</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>14</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Jul</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chlamydia pneumoniae infection in atherosclerotic lesion development through oxidative stress: a brief overview.</ArticleTitle>
        <Pagination>
          <StartPage>15105</StartPage>
          <EndPage>15120</EndPage>
          <MedlinePgn>15105-20</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms140715105</ELocationID>
        <Abstract>
          <AbstractText>Chlamydia pneumoniae, an obligate intracellular pathogen, is known as a leading cause of respiratory tract infections and, in the last two decades, has been widely associated with atherosclerosis by seroepidemiological studies, and direct detection of the microorganism within atheroma. C. pneumoniae is presumed to play a role in atherosclerosis for its ability to disseminate via peripheral blood mononuclear cells, to replicate and persist within vascular cells, and for its pro-inflammatory and angiogenic effects. Once inside the vascular tissue, C. pneumoniae infection has been shown to induce the production of reactive oxygen species in all the cells involved in atherosclerotic process such as macrophages, platelets, endothelial cells, and vascular smooth muscle cells, leading to oxidative stress. The aim of this review is to summarize the data linking C. pneumoniae-induced oxidative stress to atherosclerotic lesion development.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Di Pietro</LastName>
            <ForeName>Marisa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health and Infectious Diseases, "Sapienza" University, Rome 00185, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Filardo</LastName>
            <ForeName>Simone</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Santis</LastName>
            <ForeName>Fiorenzo</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sessa</LastName>
            <ForeName>Rosa</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002690" MajorTopicYN="N">Chlamydia Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016993" MajorTopicYN="N">Chlamydophila pneumoniae</DescriptorName>
          <QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23877837</ArticleId>
        <ArticleId IdType="pmc">PMC3742290</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms140715105</ArticleId>
        <ArticleId IdType="pii">ijms140715105</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wong B.W., Meredith A., Lin D., McManus B.M. The biological role of inflammation in atherosclerosis. Biol. Chem. 2012;393:1005–1011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3520003</ArticleId>
            <ArticleId IdType="pubmed">22944699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenfeld M.E., Campbell L.A. Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb. Haemost. 2011;106:858–867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22012133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramirez J.A. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann. Intern. Med. 1996;125:979–982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8967709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson L.A., Campbell L.A., Kuo C.C., Rodriguez D.I., Lee A., Grayston J.T. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J. Infect. Dis. 1997;176:292–295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9207386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maass M., Bartels C., Engel P.M., Mamat U., Sievers H.H. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J. Am. Coll. Cardiol. 1998;31:827–832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9525555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apfalter P., Loidl M., Nadrchal R., Makristathis A., Rotter M., Bergmann M., Polterauer P., Hirschl A.M. Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens. Eur. J. Clin. Microbiol. Infect. Dis. 2000;19:305–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10834822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoborg R.V. Chlamydia persistence—A tool to dissect Chlamydia-host interactions. Microbes. Infect. 2011;13:649–662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3636554</ArticleId>
            <ArticleId IdType="pubmed">21458583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa C.P., Kirschning C.J., Busch D., Dürr S., Jennen L., Heinzmann U., Prebeck S., Wagner H., Miethke T. Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae. Eur. J. Immunol. 2002;32:2460–2470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12207330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalayoglu M.V. Chlamydial heat shock protein 60 and lipopolysaccharide: Potential virulence determinants in atherogenesis. Curr. Drug Targets Inflamm. Allergy. 2002;1:249–255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14561189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jha H.C., Srivastava P., Prasad J., Mittal A. Chlamydia pneumoniae heat shock protein 60 enhances expression of ERK, TLR-4 and IL-8 in atheromatous plaques of coronary artery disease patients. Immunol. Invest. 2011;40:206–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21192737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Münzel T., Gori T., Bruno R.M., Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur. Heart J. 2010;31:2741–2748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20974801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen K., Keaney J.F., Jr Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease. Curr. Atheroscler. Rep. 2012;14:476–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3872835</ArticleId>
            <ArticleId IdType="pubmed">22956414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azenabor A.A., Yang S., Job G., Adedokun O.O. Elicitation of reactive oxygen species in Chlamydia pneumoniae-stimulated macrophages: A Ca2+-dependent process involving simultaneous activation of NADPH oxidase and cytochrome oxidase genes. Med. Microbiol. Immunol. 2005;194:91–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15197588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kälvegren H., Bylin H., Leanderson P., Richter A., Grenegård M., Bengtsson T. Chlamydia pneumoniae induces nitric oxide synthase and lipoxygenase-dependent production of reactive oxygen species in platelets. Effects on oxidation of low density lipoproteins. Thromb. Haemost. 2005;94:327–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16113822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chahine M.N., Deniset J., Dibrov E., Hirono S., Blackwood D.P., Austria J.A., Pierce G.N. Oxidized LDL promotes the mitogenic actions of Chlamydia pneumoniae in vascular smooth muscle cells. Cardiovasc. Res. 2011;92:476–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22072707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreutmayer S., Csordas A., Kern J., Maass V., Almanzar G., Offterdinger M., Ollinger R., Maass M., Wick G. Chlamydia pneumoniae infection acts as an endothelial stressor with the potential to initiate the earliest heat shock protein 60-dependent inflammatory stage of atherosclerosis. Cell Stress Chaperones. 2013;18:259–268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3631098</ArticleId>
            <ArticleId IdType="pubmed">23192457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grayston J.T. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J. Infect. Dis. 2000;181:s402–s410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10839724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sessa R., Di Pietro M., Schiavoni G., Petrucca A., Cipriani P., Zagaglia C., Nicoletti M., Santino I., del Piano M. Measurement of Chlamydia pneumoniae bacterial load in peripheral blood mononuclear cells may be helpful to assess the state of chlamydial infection in patients with carotid atherosclerotic disease. Atherosclerosis. 2007;195:e224–e230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17575984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S.S., Tondella M.L., Bajpai A., Mathew A.G., Mehranpour P., Li W., Kacharava A.G., Fields B.S., Austin H., Zafari A.M. Circulating Chlamydia pneumoniae DNA and advanced coronary artery disease. Int. J. Cardiol. 2007;118:215–219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17023075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Pietro M., Schiavoni G., Sessa V., Pallotta F., Costanzo G., Sessa R. Chlamydia pneumoniae and osteoporosis-associated bone loss: A new risk factor? Osteoporos. Int. 2013;24:1677–1682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23160916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Pietro M., Filardo S., Cazzavillan S., Segala C., Bevilacqua P., Bonoldi E., D’Amore E.S., Rassu M., Sessa R. Could past Chlamydial vascular infection promote the dissemination of Chlamydia pneumoniae to the brain? J. Biol. Regul. Homeost. Agents. 2013;27:155–164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23489695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moulder J.W. Interaction of chlamydiae and host cells in vitro. Microbiol. Rev. 1991;55:143–190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC372804</ArticleId>
            <ArticleId IdType="pubmed">2030670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hogan R.J., Mathews S.A., Mukhopadhyay S., Summersgill J.T., Timms P. Chlamydial persistence: Beyond the biphasic paradigm. Infect. Immun. 2004;72:1843–1855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC375192</ArticleId>
            <ArticleId IdType="pubmed">15039303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Pietro M., Tramonti A., de Santis F., de Biase D., Schiavoni G., Filardo S., Zagaglia C., Sessa R. Analysis of gene expression in penicillin G induced persistence of Chlamydia pneumoniae. J. Biol. Regul. Homeost. Agents. 2012;26:277–284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22824742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Pietro M., de Santis F., de Biase D., Sessa R. The elusive but pathogenic peptidoglycan of Chlamydiae. Eur. J. Inflamm. 2013;11:257–260.</Citation>
        </Reference>
        <Reference>
          <Citation>Gieffers J., Füllgraf H., Jahn J., Klinger M., Dalhoff K., Katus H.A., Solbach W., Maass M. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001;103:351–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11157684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deniset J.F., Pierce G.N. Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis. Fundam. Clin. Pharmacol. 2010;24:607–617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saikku P., Leinonen M., Mattila K., Ekman M.R., Nieminen M.S., Mäkelä P.H., Huttunen J.K., Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2902492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sessa R., Di Pietro M., Santino I., del Piano M., Varveri A., Dagianti A., Penco M. Chlamydia pneumoniae infection and atherosclerotic coronary disease. Am. Heart J. 1999;137:1116–1119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10347340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boman J., Hammerschlag M.R. Chlamydia pneumoniae and atherosclerosis: Critical assessment of diagnostic methods and relevance to treatment studies. Clin. Microbiol. Rev. 2002;15:1–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC118057</ArticleId>
            <ArticleId IdType="pubmed">11781264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voorend M., Faber C.G., van der Ven A.J., Kessels F., Bruggeman C.A., Lodder J. Chlamydia pneumoniae is a likely risk factor for ischemic stroke in young patients. J. Stroke Cerebrovasc. Dis. 2004;13:85–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17903955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jha H.C., Srivastava P., Sarkar R., Prasad J., Mittal A. Chlamydia pneumoniae IgA and elevated level of IL-6 may synergize to accelerate coronary artery disease. J. Cardiol. 2008;52:140–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18922388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swierszcz J., Jacek D.S., Milewicz T., Krzysiek J., Sztefko K., Galicka-Latała D. One-year observation of inflammatory markers in patients with aortic valve stenosis who expressed high or low Chlamydia pneumoniae antibody titers. J. Heart Valve Dis. 2012;21:599–607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23167224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi R., Khandelwal B., Joshi D., Gupta O.P. Chlamydophila pneumoniae infection and cardiovascular disease. N. Am. J. Med. Sci. 2013;5:169–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3632020</ArticleId>
            <ArticleId IdType="pubmed">23626952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowell S.F., Peeling R.W., Boman J., Carlone G.M., Fields B.S., Guarner J., Hammerschlag M.R., Jackson L.A., Kuo C.C., Maass M., et al.  C. pneumoniae Workshop Participants. Standardizing Chlamydia pneumoniae assays: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada) Clin. Infect. Dis. 2001;33:492–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11462186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shor A., Phillips J.I. Histological and ultrastructural findings suggesting an initiating role for Chlamydia pneumoniae in the pathogenesis of atherosclerosis. Cardiovasc. J. S. Afr. 2000;11:16–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11447462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sessa R., Di Pietro M., Schiavoni G., Nicoletti M., Soda G., Nardoni S., Bosco D., Santino I., Cipriani P., del Piano M. Detection of Chlamydia pneumoniae in atherosclerotic coronary arteries. Int. J. Immunopathol. Pharmacol. 2004;17:301–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15461864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Virok D., Kis Z., Kari L., Barzo P., Sipka R., Burian K., Nelson D.E., Jackel M., Kerenyi T., Bodosi M., et al.  Chlamydophila pneumoniae and human cytomegalovirus in atherosclerotic carotid plaques–combined presence and possible interactions. Acta Microbiol. Immunol. Hung. 2006;53:35–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16696549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sessa R., di Pietro M., Schiavoni G., Galdiero M., Cipriani P., Romano S., Zagaglia C., Santino I., Faccilongo S., del Piano M. Chlamydia pneumoniae in asymptomatic carotid atherosclerosis. Int. J. Immunopathol. Pharmacol. 2006;19:111–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16569349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jha H.C., Srivastava P., Divya A., Prasad J., Mittal A. Prevalence of Chlamydophila pneumoniae is higher in aorta and coronary artery than in carotid artery of coronary artery disease patients. APMIS. 2009;117:905–911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20078556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atik B., Johnston S.C., Dean D. Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke. PLoS One. 2010;5 doi: 10.1371/journal.pone.0011026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0011026</ArticleId>
            <ArticleId IdType="pmc">PMC2882946</ArticleId>
            <ArticleId IdType="pubmed">20543948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luque A., Turu M.M., Rovira N., Juan-Babot J.O., Slevin M., Krupinski J. Early atherosclerotic plaques show evidence of infection by Chlamydia pneumoniae. Front. Biosci. 2012;4:2423–2432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22652649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fong I.W., Chiu B., Viira E., Fong M.W., Jang D., Mahony J. Rabbit model for Chlamydia pneumoniae infection. J. Clin. Microbiol. 1997;35:48–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC229510</ArticleId>
            <ArticleId IdType="pubmed">8968879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muhlestein J.B. Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. J. Infect. Dis. 2000;181:S505–S507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10839748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blessing E., Campbell L.A., Rosenfeld M.E., Chough N., Kuo C.C. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis. 2001;158:13–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11500169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ezzahiri R., Stassen F.R., Kurvers H.A., van Pul M.M., Kitslaar P.J., Bruggeman C.A. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur. J. Vasc. Endovasc. Surg. 2003;26:88–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12819654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S., Shimada K., Zhang W., Huang G., Crother T.R., Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J. Immunol. 2010;185:5619–5627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3046880</ArticleId>
            <ArticleId IdType="pubmed">20935201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin F.Y., Lin Y.W., Huang C.Y., Chang Y.J., Tsao N.W., Chang N.C., Ou K.L., Chen T.L., Shih C.M., Chen Y.H. GroEL1, a heat shock protein 60 of Chlamydia pneumoniae, induces lectin-like oxidized low-density lipoprotein receptor 1 expression in endothelial cells and enhances atherogenesis in hypercholesterolemic rabbits. J. Immunol. 2011;186:4405–4414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21383245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C.Y., Shih C.M., Tsao N.W., Chen Y.H., Li C.Y., Chang Y.J., Chang N.C., Ou K.L., Lin C.Y., Lin Y.W., et al.  GroEL1, from Chlamydia pneumoniae, induces vascular adhesion molecule 1 expression by p37(AUF1) in endothelial cells and hypercholesterolemic rabbit. PLoS One. 2012;7 doi: 10.1371/journal.pone.0042808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0042808</ArticleId>
            <ArticleId IdType="pmc">PMC3416774</ArticleId>
            <ArticleId IdType="pubmed">22900050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moazed T.C., Kuo C., Grayston J.T., Campbell L.A. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J. Infect. Dis. 1997;175:883–890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9086145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moazed T.C., Kuo C.C., Grayston J.T., Campbell L.A. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J. Infect. Dis. 1998;177:1322–1325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9593019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Kruif M.D., van Gorp E.C., Keller T.T., Ossewaarde J.M., ten Cate H. Chlamydia pneumoniae infections in mouse models: Relevance for atherosclerosis research. Cardiovasc. Res. 2005;65:317–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15639470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Little C.S., Bowe A., Lin R., Litsky J., Fogel R.M., Balin B.J., Fresa-Dillon K.L. Age alterations in extent and severity of experimental intranasal infection with Chlamydophila pneumoniae in BALB/c mice. Infect. Immun. 2005;73:1723–1734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1064908</ArticleId>
            <ArticleId IdType="pubmed">15731073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boman J., Söderberg S., Forsberg J., Birgander L.S., Allard A., Persson K., Jidell E., Kumlin U., Juto P., Waldenström A., Wadell G. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J. Infect. Dis. 1998;178:274–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9652454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sessa R., Di Pietro M., Schiavoni G., Santino I., Cipriani P., Romano S., Penco M., del Piano M. Prevalence of Chlamydia pneumoniae in peripheral blood mononuclear cells in Italian patients with acute ischaemic heart disease. Atherosclerosis. 2001;159:521–525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11730834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smieja M., Mahony J., Petrich A., Boman J., Chernesky M. Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: A systematic review. BMC Infect. Dis. 2002;2 doi: 10.1186/1471-2334-2-21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2334-2-21</ArticleId>
            <ArticleId IdType="pmc">PMC130041</ArticleId>
            <ArticleId IdType="pubmed">12359046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kern J.M., Maass V., Maass M. Chlamydia pneumoniae adversely modulates vascular cell properties by direct interaction with signalling cascades. Thromb. Haemost. 2009;102:1064–1070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19967136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Pietro M., Schiavoni G., del Piano M., Shaik Y., Boscolo P., Caraffa A., Grano M., Teté S., Conti F., Sessa R. Chlamydia pneumoniae and atherosclerosis: The role of mast cells. J. Biol. Regul. Homeost. Agents. 2009;23:65–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19589286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oksaharju A., Lappalainen J., Tuomainen A.M., Pussinen P.J., Puolakkainen M., Kovanen P.T., Lindstedt K.A. Pro-atherogenic lung and oral pathogens induce an inflammatory response in human and mouse mast cells. J. Cell. Mol. Med. 2009;13:103–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3823039</ArticleId>
            <ArticleId IdType="pubmed">18298659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalayoglu M.V., Miranpuri G.S., Golenbock D.T., Byrne G.I. Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect. 1999;1:409–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10602673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao F., Castrillo A., Tontonoz P., Re F., Byrne G.I. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect. Immun. 2007;75:753–759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1828523</ArticleId>
            <ArticleId IdType="pubmed">17145941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitazawa T., Fukushima A., Okugawa S., Yanagimoto S., Tsukada K., Tatsuno K., Koike K., Kimura S., Kishimoto T., Shibasaki Y., et al.  Chlamydophilal antigens induce foam cell formation via c-Jun NH2-terminal kinase. Microbes Infect. 2007;9:1410–1414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17913539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He P., Mei C., Cheng B., Liu W., Wang Y., Wan J. Chlamydia pneumoniae induces macrophage-derived foam cell formation by up-regulating acyl-coenzyme A: Cholesterol acyltransferase 1. Microbes Infect. 2009;11:157–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19049899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W., He P., Cheng B., Mei C.L., Wang Y.F., Wan J.J. Chlamydia pneumoniae disturbs cholesterol homeostasis in human THP-1 macrophages via JNK-PPARγ dependent signal transduction pathways. Microbes Infect. 2010;12:1226–1235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20870032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Netea M.G., Selzman C.H., Kullberg B.J., Galama J.M., Weinberg A., Stalenhoef A.F., van der Meer J.W., Dinarello C.A. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur. J. Immunol. 2000;30:541–549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10671210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaydos C.A. Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J. Infect. Dis. 2000;181:S473–478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10839742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kol A., Sukhova G.K., Lichtman A.H., Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998;98:300–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9711934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Pietro M., de Santis F., Schiavoni G., Filardo S., Sessa R. Resveratrol in Chlamydia pneumoniae induced foam cell formationand interleukin-17A sythesis. J. Biol. Regul. Homeost. Agents. 2013;27 in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23830400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krüll M., Klucken A.C., Wuppermann F.N., Fuhrmann O., Magerl C., Seybold J., Hippenstiel S., Hegemann J.H., Jantos C.A., Suttorp N. Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J. Immunol. 1999;162:4834–4841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10202027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molestina R.E., Miller R.D., Ramirez J.A., Summersgill J.T. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect. Immun. 1999;67:1323–1330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC96464</ArticleId>
            <ArticleId IdType="pubmed">10024578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kothe H., Dalhoff K., Rupp J., Müller A., Kreuzer J., Maass M., Katus H.A. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 2000;101:1760–1763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10769273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Högdahl M., Söderlund G., Kihlström E. Expression of chemokines and adhesion molecules in human coronary artery endothelial cells infected with Chlamydia (Chlamydophila) pneumoniae. APMIS. 2008;116:1082–1088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19133011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fryer R.H., Schwobe E.P., Woods M.L., Rodgers G.M. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J. Investig. Med. 1997;45:168–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9154297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dechend R., Maass M., Gieffers J., Dietz R., Scheidereit C., Leutz A., Gulba D.C. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: A potential link to accelerated arteriosclerosis. Circulation. 1999;100:1369–1373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10500035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Summersgill J.T., Molestina R.E., Miller R.D., Ramirez J.A. Interactions of Chlamydia pneumoniae with human endothelial cells. J. Infect. Dis. 2000;181:s479–s482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10839743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang A., Al-Kuhlani M., Johnston S.C., Ojcius D.M., Chou J., Dean D. Transcription factor complex AP-1 mediates inflammation initiated by Chlamydia pneumoniae infection. Cell Microbiol. 2013;15:779–794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3593943</ArticleId>
            <ArticleId IdType="pubmed">23163821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Netea M.G., Kullberg B.J., Galama J.M., Stalenhoef A.F., Dinarello C.A., van der Meer J.W. Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. Eur. J. Immunol. 2002;32:1188–1195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11932927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X., Coriolan D., Schultz K., Golenbock D.T., Beasley D. Toll-like receptor 2 mediates persistent chemokine release by Chlamydia pneumoniae-infected vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2005;25:2308–2314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16179594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Touyz R.M., Briones A.M., Sedeek M., Burger D., Montezano A.C. NOX isoforms and reactive oxygen species in vascular health. Mol. Interv. 2011;11:27–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21441119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azenabor A.A., Muili K., Akoachere J.F., Chaudhry A. Macrophage antioxidant enzymes regulate Chlamydia pneumoniae chronicity: Evidence of the effect of redox balance on host-pathogen relationship. Immunobiology. 2006;211:325–339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16716802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Airenne S., Surcel H.M., Alakärppä H., Laitinen K., Paavonen J., Saikku P., Laurila A. Chlamydia pneumoniae infection in human monocytes. Infect. Immun. 1999;67:1445–1449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC96479</ArticleId>
            <ArticleId IdType="pubmed">10024593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannonen L., Kamping E., Penttilä T., Puolakkainen M. IFN-gamma induced persistent Chlamydia pneumoniae infection in HL and Mono Mac 6 cells: Characterization by real-time quantitative PCR and culture. Microb. Pathog. 2004;36:41–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14643639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters J., Hess S., Endlich K., Thalmann J., Holzberg D., Kracht M., Schaefer M., Bartling G., Klos A. Silencing or permanent activation: Host-cell responses in models of persistent Chlamydia pneumoniae infection. Cell Microbiol. 2005;7:1099–1108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16008577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klos A., Thalmann J., Peters J., Gérard H.C., Hudson A.P. The transcript profile of persistent Chlamydophila (Chlamydia) pneumoniae in vitro depends on the means by which persistence is induced. FEMS Microbiol. Lett. 2009;291:120–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19077059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azenabor A.A., Job G., Yang S. Induction of lipoprotein lipase gene expression in Chlamydia pneumoniae-infected macrophages is dependent on Ca2+ signaling events. Biol. Chem. 2004;385:67–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14977048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mei C.L., He P., Cheng B., Liu W., Wang Y.F., Wan J.J. Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways. Cell Biol. Int. 2009;33:301–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19114110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaraei K., Campbell L.A., Zhu X., Liles W.C., Kuo C.C., Rosenfeld M.E. Chlamydia pneumoniae augments the oxidized low-density lipoprotein-induced death of mouse macrophages by a caspase-independent pathway. Infect. Immun. 2005;73:4315–4322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1168605</ArticleId>
            <ArticleId IdType="pubmed">15972525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouwman J.J., Visseren F.L., Bevers L.M., van der Vlist W.E., Bouter K.P., Diepersloot R.J. Azithromycin reduces Chlamydia pneumoniae-induced attenuation of eNOS and cGMP production by endothelial cells. Eur. J. Clin. Invest. 2005;35:573–582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16128864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Projahn D., Koenen R.R. Platelets: Key players in vascular inflammation. J. Leukoc. Biol. 2012;92:1167–1175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22923486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kälvegren H., Andersson J., Grenegård M., Bengtsson T. Platelet activation triggered by Chlamydia pneumoniae is antagonized by 12-lipoxygenase inhibitors but not cyclooxygenase inhibitors. Eur. J. Pharmacol. 2007;566:20–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17459368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Bannawi A., Al-Wesebai K., Taha S., Bakhiet M. Chlamydia pneumoniae induces chemokine expression by platelets in patients with atherosclerosis. Med. Princ. Pract. 2011;20:438–443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21757933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleissner F., Thum T. Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Antioxid. Redox. Signal. 2011;15:933–948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3135185</ArticleId>
            <ArticleId IdType="pubmed">20712407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C., Chai H., Wang X., Lin P.H., Yao Q. Chlamydia heat shock protein 60 decreases expression of endothelial nitric oxide synthase in human and porcine coronary artery endothelial cells. Cardiovasc. Res. 2009;83:768–777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2725775</ArticleId>
            <ArticleId IdType="pubmed">19443423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wick G., Knoflach M., Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu. Rev. Immunol. 2004;22:361–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15032582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nazzal D., Cantero A.V., Therville N., Segui B., Negre-Salvayre A., Thomsen M., Benoist H. Chlamydia pneumoniae alters mildly oxidized low-density lipoprotein-induced cell death in human endothelial cells, leading to necrosis rather than apoptosis. J. Infect. Dis. 2006;193:136–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16323142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivera J., Walduck A.K., Strugnell R.A., Sobey C.G., Drummond G.R. Chlamydia pneumoniae induces a pro-inflammatory phenotype in murine vascular smooth muscle cells independently of elevating reactive oxygen species. Clin. Exp. Pharmacol. Physiol. 2012;39:218–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22211630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirono S., Dibrov E., Hurtado C., Kostenuk A., Ducas R., Pierce G.N. Chlamydia pneumoniae stimulates proliferation of vascular smooth muscle cells through induction of endogenous heat shock protein 60. Circ. Res. 2003;93:710–716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14500333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Li X., Zhang L., Wang B., Zhang T., Ye J. Chlamydophila (Chlamydia) pneumoniae infection promotes vascular smooth muscle cell adhesion and migration through IQ domain GTPase-activating protein 1. Microb. Pathog. 2012;53:207–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22835851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasu S., LaVerda D., Qureshi N., Golenbock D.T., Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ. Res. 2001;89:244–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11485974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deby-Dupont G., Mouithys-Mickalad A., Serteyn D., Lamy M., Deby C. Resveratrol and curcumin reduce the respiratory burst of Chlamydia-primed THP-1 cells. Biochem. Biophys. Res. Commun. 2005;333:21–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15939398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mouithys-Mickalad A., Deby-Dupont G., Dogne J.M., de Leval X., Kohnen S., Navet R., Sluse F., Hoebeke M., Pirotte B., Lamy M. Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1) Biochem. Biophys. Res. Commun. 2004;325:1122–1130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15555544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dechend R., Gieffers J., Dietz R., Joerres A., Rupp J., Luft F.C., Maass M. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation. 2003;108:261–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12860900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prochnau D., Rödel J., Prager K., Kuersten D., Heller R., Straube E., Figulla H.R. Induced expression of lectin-like oxidized ldl receptor-1 in vascular smooth muscle cells following Chlamydia pneumoniae infection and its down-regulation by fluvastatin. Acta Microbiol. Immunol. Hung. 2010;57:147–155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20587387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Horke S., Förstermann U. Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol. Sci. 2013;34:313–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23608227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004;350:1495–1504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15007110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy S.A., Cannon C.P., Wiviott S.D., McCabe C.H., Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J. Am. Coll. Cardiol. 2009;54:2358–2362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20082923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadowitz B., Seymour K., Costanza M.J., Gahtan V. Statin therapy—Part II: Clinical considerations for cardiovascular disease. Vasc. Endovascular. Surg. 2010;44:421–433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20547576</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
